JP Morgan Healthcare Conferences21.q4cdn.com/104148044/files/doc_presentations/... · NOT FOR...
Transcript of JP Morgan Healthcare Conferences21.q4cdn.com/104148044/files/doc_presentations/... · NOT FOR...
NOT FOR PRODUCT PROMOTIONAL USE
JP MorganHealthcare Conference
January 12, 2016
Giovanni CaforioChief Executive Officer
1
NOT FOR PRODUCT PROMOTIONAL USE
Forward-Looking InformationThis presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.
In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
This presentation also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.
22
NOT FOR PRODUCT PROMOTIONAL USE
Our Strategic Foundation
People helping patients in their fight against serious disease
I N N O VAT E I M P R O V EI N T E G R AT E
Diversified Specialty BioPharma
Best of BIOTECH
Best of PHARMA
3
NOT FOR PRODUCT PROMOTIONAL USE
2015: Beginning A New Chapter
Leading in Immuno-Oncology Diversified in-line portfolio
A Strong Foundation for Future Growth
Early Trial Stops3FDA Approvals7
43 Global launches
4
NOT FOR PRODUCT PROMOTIONAL USE
Drive business performance
Leadership in Immuno-Oncology
Diversify for long-term growth
Business Development and Capital Allocation
Strategic Priorities
5
NOT FOR PRODUCT PROMOTIONAL USE
2015: Leading in Immuno-Oncology
MELANOMA
LUNG
RENAL
• Only PD-1 indicated for all 2nd lineNSCLC patients
• No testing requirement
• Strong access and reimbursement
• Broad range of treatment options (Mono and combination therapy, 1st and 2nd line, adjuvant)
• First I-O combination regimen approved
• First I-O agent in 2nd line
• Meaningful improvement over a standard of care
6
NOT FOR PRODUCT PROMOTIONAL USE
2015: Leading in Immuno-Oncology
Strong US commercial execution
1/2
1/9
1/16
1/23
1/30 2/
62/
132/
202/
27 3/6
3/13
3/20
3/27 4/
34/
104/
174/
24 5/1
5/8
5/15
5/22
5/29 6/
56/
126/
196/
26 7/3
7/10
7/17
7/24
7/31 8/
78/
148/
218/
28 9/4
9/11
9/18
9/25
10/2
10/9
10/1
610
/23
10/3
011
/611
/13
11/2
011
/27
12/4
12/1
1
I-O Weekly Sales Trends
Total IO Market – Weekly IMS DDD + Xponent
Yervoy
Opdivo
BMS I-OPortfolio
Keytruda
Note: This information is an estimate derived from the use of information under license from the following IMS Health information services: Xponent & DDD weekly dollars, for the period of 1/2/2015 through 12/31/2015. IMS expressly reserves all rights, including rights of copying, distribution and republication.
7
NOT FOR PRODUCT PROMOTIONAL USE
2016: Leading in Immuno-Oncology
Tumor Study Design Hodgkin Lymphoma
CheckMate -205Monotherapy single arm studyin second line
Head and NeckCheckMate -141
Monotherapy vs. standard of carein second line
Non-Hodgkin Lymphoma
CheckMate -139
Monotherapy single-arm study in relapsed/refractory diffuse largeB-cell lymphoma
BladderCheckMate -275
Monotherapy single arm studyin second line bladder
GlioblastomaCheckMate -143
Monotherapy vs. standard of carein recurrent glioblastoma
1L NSCLCCheckMate -026
Monotherapy vs. chemo in first-line PD-L1 expressers
Potentially Registrational Data
8
NOT FOR PRODUCT PROMOTIONAL USE
2016: Diversifying in Immuno-Oncology
Patients who do not respondto Opdivo +/- Yervoy
Patients who progress after treatment with Opdivo +/- Yervoy
Additional tumors, including where signals are not sufficient
Improve outcomes through combinations
Next wave of innovation: addressing unmet need
9
NOT FOR PRODUCT PROMOTIONAL USE
8 Additional I-O Assetsin Clinical
Development
2016: Diversifying in Immuno-Oncology
NK cell
T cell
BMS assets beginning clinical studies in 2016
Tumor Microenvironment
T Cell Activation
NK Cell Activation
Next wave of innovation: areas of focus Priming & Activation
AntigenPresentation
AntigenRelease
T Cell Trafficking and Infiltration
anti-CSF1R IDO
anti-CD73
anti-LAG3
Urelumab(anti-CD137)
anti-GITR
anti-OX40
Lirilumab(anti-KIR)
10
NOT FOR PRODUCT PROMOTIONAL USE
0%
10%
20%
30%
40%
50%
60%
70%
80%
10/2
4/14
11/2
1/14
12/1
9/14
1/16
/15
2/13
/15
3/13
/15
4/10
/15
5/8/
15
6/5/
15
7/3/
15
7/31
/15
8/28
/15
9/25
/15
AF/V
TE-T
xSh
are
0%
10%
20%
30%
40%
50%
60%
70%
80%
10/2
4/14
11/2
1/14
12/1
9/14
1/16
/15
2/13
/15
3/13
/15
4/10
/15
5/8/
15
6/5/
15
7/3/
15
7/31
/15
8/28
/15
9/25
/15
AF/V
TE-T
x S
hare
U.S. NBRx NOAC Market Share –Cardiologists (AFib + VTE-Tx)
U.S. NBRx NOAC Market Share –All Physicians (AFib + VTE-Tx)
Note: Eliquis and Xarelto (all form strengths) are factored for AF and VTE-Tx indications. Pradaxa and Savaysa are unfactored and include volume across all approved indications. Source: IMS SDI VECTOR. NBRx (New to Brand Rx) = Naïve + Switch to Rx.
Pradaxa TotalEliquis AF/VTE-Tx Savaysa TotalXarelto AF/VTE-TX
Strong performance trends – establishing global leadership
11
NOT FOR PRODUCT PROMOTIONAL USE
Genetically Defined Diseases
Monogenic diseasesSentinel populations
(eg, Duchenne Muscular Dystrophy, Progressive Supranuclear Palsy)
CardiovascularHeart Failure Thrombosis
ImmunoscienceNovel mechanisms
in RA and IBDLupus
Fibrotic DiseasesLungLiver
Kidney
Pursuing Transformational MedicinesBeyond Immuno-Oncology
12
NOT FOR PRODUCT PROMOTIONAL USE
Capital Allocation:A Balanced Approach
Continue to be in a solid financial position:
• Strong balance sheet
• Business development remains a top priority
• Dividend commitment
7th consecutive annual increase
13
NOT FOR PRODUCT PROMOTIONAL USE
Select Recent Partnerships
Immuno-science
Fibrotic DiseasesI-O
Cardio-vascular
Academic Partnerships
14
NOT FOR PRODUCT PROMOTIONAL USE
BMS: Poised for Growth
Significant growth opportunity driven byI-O and Eliquis
Strategic investments behind growth brands
Advancing a diverse and innovative pipeline
Balanced approach to capital allocation
Focused business development
15
NOT FOR PRODUCT PROMOTIONAL USE
JP MorganHealthcare Conference
January 12, 2016
Giovanni CaforioChief Executive Officer
16